{"brief_title": "An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (MK0431-023)", "brief_summary": "The purpose of this study is to determine the safety and effectiveness of an investigational drug in patients with Type 2 Diabetes Mellitus.", "condition": ["Diabetes Mellitus, Type 2"], "intervention_type": ["Drug", "Drug", "Drug", "Drug"], "intervention_name": ["Comparator: sitagliptin 100 mg", "Comparator: sitagliptin 200 mg", "Comparator: placebo", "Comparator: pioglitazone"], "description": ["sitagliptin 100 mg oral tablet once daily for 54 weeks", "sitagliptin 200 mg (2- 100 mg oral tablets) once daily for 54 weeks", "placebo oral tablet once daily during Phase A (Weeks 0-18)", "pioglitazone 30 mg oral tablet once daily during Phase B (Weeks 18-54)"], "arm_group_label": ["Sitagliptin 100 mg", "Sitagliptin 200 mg", "Placebo/Pioglitazone", "Placebo/Pioglitazone"], "criteria": "Inclusion Criteria: - Patients at least 18 years of age and not older than 75 who have a specific type of diabetes called Type 2 Diabetes Mellitus Exclusion Criteria: - Younger than 18 years of age or older than 75 - Any condition, which in the opinion of the investigator, may not be in the patient's best interest to participate", "gender": "All", "minimum_age": "18 Years", "maximum_age": "75 Years", "healthy_volunteers": "No", "mesh_term": ["Diabetes Mellitus", "Diabetes Mellitus, Type 2", "Pioglitazone", "Sitagliptin Phosphate"], "id": "NCT00094757"}